Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on MORTICE LTD. We currently have 5 research reports from 2 professional analysts.
|28Dec16 09:29||RNS||Result of AGM|
|28Dec16 07:00||RNS||Half-year Report|
|23Dec16 07:00||RNS||Proposed £2.3m Placing|
|02Dec16 11:51||RNS||Notice of AGM|
|17Oct16 07:00||RNS||Trading update|
|19Sep16 07:00||RNS||O&G appointed to £60m cleaning framework|
|30Aug16 07:00||RNS||Final Results|
Frequency of research reports
Research reports on
Strong interim results
10 Jan 17
Once again, the group has demonstrated its ability to deliver significant growth through a combination of organic and acquisitive investment. The opportunity in India remains exciting and there is still significant scope for scalability across the group’s target markets and cross-selling potential across its client base. An additional investment attraction is the group’s high level of revenue visibility driven by its long-term contract base and high contract renewal rates. We retain our 100p target price.
17 Oct 16
Avacta* (AVCT): Act now (CORP) | Tristel* (TSTL): A strong FY 2016 (CORP) | Bioventix* (BVXP): FY 2016 results (CORP) | Elecosoft* (ELCO): SaaS model strengthened through acquisition (CORP) | Lok’nStore* (LOK): NAV up 28% (CORP) | Omega Diagnostics* (ODX): Mid year trading update (CORP) | Mortice* (MORT): Positive trading update (CORP)
Support services opportunity
31 Aug 16
In our view, Mortice is an attractive investment opportunity with strong management and brands, a positive long-term economic backdrop delivering an above average revenue growth opportunity, a large customer base with relatively low customer and sector concentration risk, high contract renewal rates, high revenue visibility and scope for geographic and service expansion through its successful acquisition programme. We initiate with a 100p target price, implying upside of 18%.
N+1 Singer - Morning Song 21-03-2017
21 Mar 17
accesso Technology (ACSO LN) Full year results in line, but key trading months still ahead | Augean (AUG LN) Double digit growth in ’16, good start to ‘17 | Earthport (EPO LN) Interims show continued top line strength | Goals Soccer Centres (GOAL LN) Good momentum under new team. It’s now all about delivery | IQE (IQE LN) FY’16 results prompt further upgrades | Microsaic Systems (MSYS LN) Challenges in 2016, strategy remains in place | mporium Group (MPM LN) Funds raised to help execute strategy | RhythmOne (RTHM LN) Dawn of the independents | ScS Group (SCS LN) Strong progress on key growth initiatives albeit comps now toughen | Sinclair Pharma (SPH LN) FY results: EBITDA ahead, Instalift™ gaining pace | Vectura Group (VEC LN) FY (9-month) results
N+1 Singer - Augean - Double digit growth in ’16, good start to ‘17
21 Mar 17
Augean reported another year of double digit growth for 2016, with profits in line with our forecasts. Sales grew by 21% excluding landfill tax, while adjusted PBT grew by 18% to £7.1m before amortisation of acquired intangibles. DPS was increased by 54% to 1.0p, 25% ahead of our estimate. The business units made further strategic progress, with revenues from their top 20 customers increasing from 42% to 43% of the total, of which 88% was under contract or a framework agreement, increasing forward visibility. There has been an encouraging start to 2017 and management is confident of delivering another year of profits growth. The shares trade on undemanding single digit multiples, offering good value.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017